CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

risdiplam

Last Updated: December 22, 2020
Result type: Reports
Project Number: SR0661-000
Product Line: Reimbursement Review

Generic Name: risdiplam

Brand Name: TBC

Manufacturer: Hoffmann La-Roche Ltd.

Therapeutic Area: Spinal muscular atrophy

Indications: ​For the treatment of spinal muscular atrophy (SMA)

Manufacturer Requested Reimbursement Criteria1: For the treatment of spinal muscular atrophy (SMA)

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 22, 2020
Call for patient/clinician input closedDecember 10, 2020
Clarification:

- Patient input submission received from Cure SMA Canada and Muscular Dystrophy Canada

Submission receivedNovember 19, 2020
Submission acceptedDecember 03, 2020
Review initiatedDecember 04, 2020
Draft CADTH review report(s) provided to sponsor for commentMarch 08, 2021
Deadline for sponsors commentsMarch 17, 2021
CADTH responses on draft review report(s) provided to sponsorApril 09, 2021
Expert committee meeting (initial)April 21, 2021
Draft recommendation issued to sponsorMay 03, 2021
To
May 05, 2021